JP2007537272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537272A5 JP2007537272A5 JP2007513317A JP2007513317A JP2007537272A5 JP 2007537272 A5 JP2007537272 A5 JP 2007537272A5 JP 2007513317 A JP2007513317 A JP 2007513317A JP 2007513317 A JP2007513317 A JP 2007513317A JP 2007537272 A5 JP2007537272 A5 JP 2007537272A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 40
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000012453 solvate Substances 0.000 claims description 30
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 25
- 125000003107 substituted aryl group Chemical group 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- -1 thiophen-yl Chemical group 0.000 claims description 13
- 206010063837 Reperfusion injury Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 206010052779 Transplant rejections Diseases 0.000 claims description 10
- 206010040070 Septic Shock Diseases 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 7
- 208000034656 Contusions Diseases 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 206010006448 Bronchiolitis Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000005232 Glossitis Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 3
- 206010020591 Hypercapnia Diseases 0.000 claims description 3
- 206010058490 Hyperoxia Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- 206010024453 Ligament sprain Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 208000034486 Multi-organ failure Diseases 0.000 claims description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 3
- 206010036600 Premature labour Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000010040 Sprains and Strains Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010069675 Ventilation perfusion mismatch Diseases 0.000 claims description 3
- 206010047924 Wheezing Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 3
- 230000006022 acute inflammation Effects 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 201000009267 bronchiectasis Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000034526 bruise Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 208000010353 central nervous system vasculitis Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 230000009519 contusion Effects 0.000 claims description 3
- 201000000159 corneal neovascularization Diseases 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 230000002349 favourable effect Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 230000000222 hyperoxic effect Effects 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 208000026440 premature labor Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 5
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims 2
- 229940124761 MMP inhibitor Drugs 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229960003776 glatiramer acetate Drugs 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 238000007363 ring formation reaction Methods 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 claims 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 claims 1
- 241000726306 Irus Species 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 108010014865 PLIalpha Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 108010039185 Tenecteplase Proteins 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 239000002597 adenosine A2 receptor agonist Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 239000000234 muscarinic M1 receptor antagonist Substances 0.000 claims 1
- 239000000536 muscarinic M2 receptor agonist Substances 0.000 claims 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 claims 1
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 claims 1
- 239000002762 nociceptin receptor agonist Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229960000216 tenecteplase Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 230000000982 vasogenic effect Effects 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 206010047470 viral myocarditis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 229960002459 alefacept Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 description 2
- 125000000068 chlorophenyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960000284 efalizumab Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000004175 fluorobenzyl group Chemical group 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57032604P | 2004-05-12 | 2004-05-12 | |
| PCT/US2005/016507 WO2005113534A2 (en) | 2004-05-12 | 2005-05-11 | Cxcr1 and cxcr2 chemokine antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011224353A Division JP2012006982A (ja) | 2004-05-12 | 2011-10-11 | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537272A JP2007537272A (ja) | 2007-12-20 |
| JP2007537272A5 true JP2007537272A5 (https=) | 2011-12-01 |
Family
ID=35149666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513317A Ceased JP2007537272A (ja) | 2004-05-12 | 2005-05-11 | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト |
| JP2011224353A Withdrawn JP2012006982A (ja) | 2004-05-12 | 2011-10-11 | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011224353A Withdrawn JP2012006982A (ja) | 2004-05-12 | 2011-10-11 | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7326729B2 (https=) |
| EP (1) | EP1745032B1 (https=) |
| JP (2) | JP2007537272A (https=) |
| KR (1) | KR20070011475A (https=) |
| CN (1) | CN1984899B (https=) |
| AU (1) | AU2005245399A1 (https=) |
| CA (1) | CA2565519A1 (https=) |
| IL (1) | IL179162A0 (https=) |
| MX (1) | MXPA06013118A (https=) |
| WO (1) | WO2005113534A2 (https=) |
| ZA (1) | ZA200609237B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005008183A1 (de) * | 2005-02-23 | 2006-08-31 | Bayer Healthcare Ag | Heterocyclylamid-substituierte Imidazole |
| AR060562A1 (es) * | 2006-04-21 | 2008-06-25 | Smithkline Beecham Corp | Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas. |
| UA95480C2 (uk) * | 2006-06-08 | 2011-08-10 | Елі Ліллі Енд Компані | Заміщені карбоксаміди |
| WO2008039876A1 (en) * | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| DE602007009865D1 (de) * | 2006-11-23 | 2010-11-25 | Novartis Ag | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten |
| CA2669579A1 (en) * | 2006-11-23 | 2008-05-29 | Novartis Ag | 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
| KR20090115749A (ko) | 2007-02-26 | 2009-11-05 | 산텐 세이야꾸 가부시키가이샤 | 우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체 |
| WO2009026248A2 (en) * | 2007-08-17 | 2009-02-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer | Hydrazide, amide, phthalimide and phthalhydrazide analogs as inhibitors of retroviral integrase |
| KR101039235B1 (ko) * | 2007-08-29 | 2011-06-07 | 메디포스트(주) | 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물 |
| GB2455539B (en) * | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| PT2356462T (pt) | 2008-11-11 | 2017-04-07 | Univ Michigan Regents | Composições e métodos anti-cxcr1 |
| CN106243023A (zh) * | 2010-09-03 | 2016-12-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| ES2688081T3 (es) * | 2011-06-13 | 2018-10-30 | Tla Targeted Immunotherapies Ab | Tratamiento de dolencias asociadas a septicemia |
| AU2013240224A1 (en) | 2012-03-30 | 2014-10-16 | Sloan-Kettering Institute For Cancer Research | S100A8/A9 as a diagnostic marker and a therapeutic target |
| WO2014062511A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| WO2014205127A2 (en) | 2013-06-18 | 2014-12-24 | New York University | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets |
| WO2015054117A1 (en) * | 2013-10-08 | 2015-04-16 | Temple University-Of The Commonwealth System Of Higher Education | Functionalized furan-2-sulfonamides exhibiting endothelial lipase inhibition |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| JP6667187B2 (ja) | 2014-09-26 | 2020-03-18 | シファ バイオメディカル コーポレーション | 抗内皮リパーゼ化合物並びに心血管疾患の治療および／または予防におけるその使用方法 |
| WO2017040742A1 (en) * | 2015-09-04 | 2017-03-09 | Dow Agrosciences Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
| JP7092356B2 (ja) * | 2016-06-22 | 2022-06-28 | フーダン ユニヴァーシティ | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
| WO2018071687A1 (en) * | 2016-10-13 | 2018-04-19 | The Regents Of The University Of California | Methods of treating pruritis |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3529247A1 (de) * | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung |
| EP0255297B1 (en) | 1986-07-31 | 1993-04-21 | Beecham Group Plc | Azabicyclic compounds, process for their preparation, and their pharmaceutical use |
| DE4412334A1 (de) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| WO1997049399A1 (en) | 1996-06-27 | 1997-12-31 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP0932405A4 (en) | 1996-06-27 | 2001-10-17 | Smithkline Beckman Corp | IL-8 RECEPTOR ANTAGONISTS |
| JP2000514049A (ja) | 1996-06-27 | 2000-10-24 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８受容体拮抗薬 |
| CZ425698A3 (cs) | 1996-06-27 | 1999-06-16 | Smithkline Beecham Corporation | Antagonista IL-8 receptoru |
| JP2000515495A (ja) | 1996-06-27 | 2000-11-21 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８レセプターアンタゴニスト |
| WO1998005328A1 (en) | 1996-08-06 | 1998-02-12 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP0934066A4 (en) | 1996-08-06 | 2001-10-17 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US6248785B1 (en) | 1996-08-06 | 2001-06-19 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| JP2000516620A (ja) | 1996-08-15 | 2000-12-12 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８レセプターアンタゴニスト |
| AR008290A1 (es) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
| JP2001527519A (ja) | 1996-08-15 | 2001-12-25 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８レセプターアンタゴニスト |
| US6335352B1 (en) | 1996-08-15 | 2002-01-01 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| EP1019035A4 (en) | 1996-08-21 | 2001-10-17 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| AR008331A1 (es) | 1997-01-23 | 1999-12-29 | Smithkline Beecham Corp | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen |
| BR9807083A (pt) | 1997-01-23 | 2000-04-18 | Smithkline Beckman Corp | Antagonistas ao receptor de il-8 |
| AR015425A1 (es) | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| AR015426A1 (es) | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion |
| SK286213B6 (sk) * | 1997-12-22 | 2008-05-06 | Bayer Corporation | Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie |
| JP2002509106A (ja) | 1998-01-20 | 2002-03-26 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| US6525069B1 (en) * | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ECSP003527A (es) | 1999-06-16 | 2002-01-25 | Smithkline Beecham Corp | Antagonistas del receptor de il - 8 v |
| CO5200760A1 (es) * | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | Antagonistas del receptor de la il-8 ceptor il-8 |
| AU6230300A (en) * | 1999-07-21 | 2001-02-13 | Kadmus Pharmaceuticals, Inc. | Substituted guanidines and the use thereof |
| DE60006057T2 (de) | 1999-12-03 | 2004-05-27 | Pfizer Products Inc., Groton | Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| AU2001241896A1 (en) | 2000-03-01 | 2001-09-12 | Smith Kline Beecham Corporation | Il-8 receptor antagonists |
| EP1265905A4 (en) | 2000-03-01 | 2003-03-12 | Smithkline Beecham Corp | IL-2 RECEPTOR ANTAGONISTS |
| AR031098A1 (es) | 2000-03-16 | 2003-09-10 | Smithkline Beecham Corp | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina |
| UY26627A1 (es) | 2000-03-24 | 2001-09-28 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
| EP1294690A2 (en) * | 2000-06-21 | 2003-03-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| RU2003126913A (ru) | 2001-02-02 | 2005-03-10 | Шеринг Корпорейшн (US) | 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| EP1270551A1 (en) * | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
| AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| US20040053953A1 (en) * | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| MY139601A (en) | 2002-10-09 | 2009-10-30 | Schering Corp | Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands |
| MXPA06007076A (es) | 2003-12-19 | 2006-08-31 | Pharmacopeia Drug Discovery | Tiadiazoles como ligandos del receptor cxc y cc-quimiocina. |
| CA2550540A1 (en) * | 2003-12-22 | 2005-07-28 | Schering Corporation | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| MX2008000366A (es) * | 2005-06-29 | 2008-03-07 | Schering Corp | Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina. |
| JP2009500328A (ja) * | 2005-06-29 | 2009-01-08 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドとしての５，６−ジ−置換オキサジアゾロピラジンおよびチアジアゾロピラジン |
-
2005
- 2005-05-11 WO PCT/US2005/016507 patent/WO2005113534A2/en not_active Ceased
- 2005-05-11 JP JP2007513317A patent/JP2007537272A/ja not_active Ceased
- 2005-05-11 CA CA002565519A patent/CA2565519A1/en not_active Abandoned
- 2005-05-11 KR KR1020067023571A patent/KR20070011475A/ko not_active Withdrawn
- 2005-05-11 AU AU2005245399A patent/AU2005245399A1/en not_active Abandoned
- 2005-05-11 US US11/126,977 patent/US7326729B2/en not_active Expired - Fee Related
- 2005-05-11 EP EP05779979.3A patent/EP1745032B1/en not_active Expired - Lifetime
- 2005-05-11 MX MXPA06013118A patent/MXPA06013118A/es active IP Right Grant
- 2005-05-11 CN CN2005800232328A patent/CN1984899B/zh not_active Expired - Fee Related
-
2006
- 2006-11-06 ZA ZA200609237A patent/ZA200609237B/xx unknown
- 2006-11-09 IL IL179162A patent/IL179162A0/en unknown
-
2007
- 2007-07-10 US US11/775,567 patent/US20070248594A1/en not_active Abandoned
-
2011
- 2011-10-11 JP JP2011224353A patent/JP2012006982A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537272A5 (https=) | ||
| CN100496493C (zh) | 2-氨基-4,5-三取代噻唑基衍生物 | |
| JP6475252B2 (ja) | ヘテロアリール置換のニコチンアミド化合物 | |
| CA2479126A1 (en) | Combination treatments for chemokine-mediated diseases | |
| AU2010333804B2 (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| CA2960446C (en) | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway | |
| JP2004536796A5 (https=) | ||
| DK2225238T3 (en) | Derivatives of 6,7-dihydro-5H-imidazoý1,2- imidazol-3-carboxylic acid amides. | |
| WO2006019962B1 (en) | Compositions and methods for treatment of colitis | |
| KR20200101400A (ko) | 아릴 및 헤테로아릴 치환된 인돌 화합물 | |
| TW200418861A (en) | Pyrrolopyridazine derivatives | |
| JP2007514746A5 (https=) | ||
| US20090069288A1 (en) | Novel therapeutic compounds | |
| RU2008141368A (ru) | Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3 | |
| JPH07267959A (ja) | イミダゾピリダジン誘導体 | |
| AU2008256869A1 (en) | Azaindazole compounds and methods of use | |
| KR20090106604A (ko) | 축합 피리딘 화합물 | |
| BRPI0720043A2 (pt) | Composto oxadiazol | |
| AU2010332955B8 (en) | 3,4,4a,10b-tetrahydro-1H-thiopyrano-[4, 3-c] isoquinoline derivatives | |
| JP7106528B2 (ja) | Ｔｒｐｖ４拮抗薬 | |
| JP2007515489A5 (https=) | ||
| WO2014194741A1 (zh) | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 | |
| CN103764145A (zh) | 作为治疗剂的异噁唑啉类化合物 | |
| AU2008256862A1 (en) | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | |
| JP2008509955A5 (https=) |